Long-Term Remission of Acquired von-Willebrand's Disease and Platelet Dysfunction after High-Dose Melphalan in a Patient with Multiple Myeloma

  • Jan Alexander Stratmann Department of Hemostaseology, Johann Wolfgang Goethe University of Frankfurt, Frankfurt am Main, Germany http://orcid.org/0000-0001-7726-6622
  • Stefan Gundermann 1Department of Hemostaseology, Johann Wolfgang Goethe University of Frankfurt, Frankfurt am Main, Germany
  • Christof Geisen German Red Cross Blood Donor Department, Frankfurt am Main, Germany
  • Alexandra Dukat Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Frankfurt am Main, Germany
  • Wolfgang Miesbach Department of Hemostaseology, Johann Wolfgang Goethe University of Frankfurt, Frankfurt am Main, Germany
Keywords: Acquired von-Willebrand's disease; Multiple myeloma; Autologous stem cell transplantation; Platelet dysfunction; Immunoglobulin


Background: Autologous stem cell transplantation is considered a standard of care treatment in eligible patients with multiple myeloma, but puts the patient at high risk for infections and bleeding complications. Acquired von-Willebrand's disease (AVWD) and acquired platelet dysfunction are rare bleeding disorders that are associated with lymphoproliferative disorders such as multiple myeloma. Patients with acquired bleeding disorders who are planned for ASCT to treat the underlying condition are considered at highest risk for bleeding complications, and optimal treatment strategies are not known.

Materials and Methods: We summarized the diagnostic and therapeutic approach to a patient affected by AVWD and acquired platelet disorder related to multiple myeloma. The patient who was planned for ASCT presented with moderate to severe bleeding symptoms.

Results: Acute bleeding episodes were successfully controlled and prevented during induction and consolidation therapy with immunoglobulins, whereas replacement of plasma-derived VW factor showed no clinical improvement. High-dose melphalan-based consolidation therapy supported with autologous stem-cell transplantation led to an immediate and sustainable rise of von-Willebrand antigen and activity and a subsequent normalization of platelet aggregation activity. After a follow-up of 40 weeks, the patient maintained normalized VW levels and platelet aggregation capacity. There were no further signs or symptoms of bleeding.

Conclusion: This case report highlights the necessity for combined supportive and causal treatment in patients with AVWD and paraproteinemic PD. High-dose melphalan with autologous stem cell support may function as a treatment option in patients with myeloma-related AVWD.


Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi133-7.

Fermand J-P, Ravaud P, Chevret S, et al. High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial. Blood 1998; 92: 3131–3136, http://www.bloodjournal.org/content/92/9/3131.full.pdf (1998).

Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.

Tiede A, Priesack J, Werwitzke S, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 6: 569–576.

Tiede A, Rand JH, Budde U, Ganser A and Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777–6785.

Callaghan MU, Wong TE and Federici AB. Treatment of acquired von Willebrand syndrome in childhood. Blood 2013; 122: 2019–2022.

Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

Einsele H, Engelhardt M, Tapprich C, et al. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol 2017.

Fruehauf S, Klaus J, Huesing J, et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 743–750.

Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

Federici AB, Stabile F, Castaman G, Canciani MT and Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92: 2707–2711.

Katagiri S, Akahane D, Amano K and Ohyashiki K. Long-term remission of acquired von Willebrand syndrome associated with multiple myeloma using bortezomib and dexamethasone therapy. Haemophilia 2016; 22: e557-e559.

Engelen ET, van Galen KPM and Schutgens REG. Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: A case report in acquired von Willebrand syndrome and review of the literature. Haemophilia 2015; 21: 419–429.

Lavin M, Brophy TM, Rawley O, et al. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. J Thromb Haemost 2016; 14: 1200–1205.

Djunic I, Elezovic I, Ilic V, et al. The effect of paraprotein on platelet aggregation. J Clin Lab Anal 2014; 28: 141–146.

How to Cite
Stratmann J, Gundermann S, Geisen C, Dukat A, Miesbach W. Long-Term Remission of Acquired von-Willebrand’s Disease and Platelet Dysfunction after High-Dose Melphalan in a Patient with Multiple Myeloma. Int J Hematol Oncol Stem Cell Res. 13(1):7-11.
Case Report(s)